MediciNova, Inc. 10-Q Summary
Business Context and Reporting Period
MediciNova is a biopharmaceutical company developing small-molecule therapies for serious diseases with unmet medical needs. Its principal programs include MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine), and MN-029 (denibulin). The filing covers the three months ended March 31, 2020, with comparative results for the three months ended March 31, 2019. The financial statements are unaudited.
Financial Performance and Liquidity
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research, development and patent expense | $1.25 million | $1.63 million | Down $0.38 million |
| General and administrative expense | $1.67 million | $3.35 million | Down $1.67 million |
| Total operating expenses | $2.92 million | $4.98 million | Down $2.05 million |
| Operating loss | $(2.92) million | $(4.98) million | Improved $2.05 million |
| Net loss | $(2.71) million | $(4.70) million | Improved $1.98 million |
| Basic and diluted loss per share | $(0.06) | $(0.11) | Improved |
| Net cash used in operating activities | $(2.88) million | $(3.03) million | Improved $0.15 million |
| Cash and cash equivalents at period-end | $61.33 million | $63.21 million | Comparable period-end balance unavailable on the balance sheet; cash flow statement shows $63.21 million |
No revenue was recognized under the Kissei collaboration agreement in either period. Accordingly, revenue-based margins are not meaningful. Stock-based compensation was $0.60 million in Q1 2020 versus $2.70 million in Q1 2019 and was a significant factor in the year-over-year expense reduction.
At March 31, 2020, total assets were $77.01 million, total liabilities were $3.82 million, working capital was $60.4 million, and stockholders’ equity was $73.20 million. The company had no debt disclosed as outstanding. Long-term deferred revenue was $1.69 million.
Financing activities provided $0.42 million, primarily from net proceeds under the 2019 at-the-market equity agreement. The company sold 68,952 shares at a weighted-average price of $6.19 per share. Management stated that available working capital was sufficient to fund operations at least through the end of 2021, but it could not assure that resources would fund all planned research and development programs.
Material Changes Versus the Prior Comparable Period
- Research, development and patent expense declined 23%, primarily because of lower performance-based stock compensation resulting from a decrease in the company’s stock price.
- General and administrative expense declined approximately 50%, also primarily due to lower performance-based stock compensation.
- Net loss narrowed from $4.70 million to $2.71 million.
- Operating cash use improved modestly, while financing proceeds declined substantially from $3.93 million in Q1 2019 to $0.42 million in Q1 2020. The prior-year financing inflow primarily reflected exercises of stock options.
- Shares outstanding increased to 43.98 million at March 31, 2020 from 43.91 million at December 31, 2019, reflecting ATM issuance and ESPP activity.
Guidance, Outlook, Risks and Unusual Items
Management expected research and development costs to increase throughout 2020 as development programs progressed and expected substantial net losses for the next several years. The company intends to advance MN-166 and MN-001 through company-funded, investigator-sponsored, government- or grant-funded trials and to pursue strategic partnerships.
COVID-19 was identified as an additional material risk. Management stated that it did not then expect a material impact on its long-term development timeline or liquidity, but also stated that it could not estimate the pandemic’s effects on operations, financial condition or liquidity. Potential impacts include clinical-trial delays, supply-chain disruption, workforce constraints, economic disruption and reduced access to capital.
Other principal risks include clinical-trial failure or delay, regulatory nonapproval, inability to raise additional capital, dependence on MN-166 and MN-001, reliance on third-party manufacturers and service providers, intellectual-property disputes, competition, inability to obtain partners, and lack of future product revenue. No material legal proceedings were disclosed, and the company reported no off-balance-sheet arrangements.
Goodwill of $9.60 million and in-process research and development of $4.80 million were carried as indefinite-lived assets and remain subject to impairment testing. The company adopted ASU 2018-13 on January 1, 2020 with no material effect.
Important Facts for Investors to Verify
- Whether the company’s $61.33 million cash balance and stated funding runway remain sufficient as clinical development spending increases.
- The timing, enrollment, results and financing sources for key MN-166 and MN-001 clinical programs.
- The potential effect of COVID-19 and other disruptions on clinical trials, suppliers and development timelines.
- The availability and future use of the $75.0 million 2019 ATM facility, including potential dilution from additional equity sales.
- Whether the Kissei collaboration’s remaining performance obligation will generate future revenue and when the $1.69 million deferred revenue may be recognized.
- Potential impairment of the $14.40 million combined goodwill and in-process research and development balances.
- The company’s ability to generate product revenue or secure partnerships before existing capital is exhausted.